Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

In the latest ASCO in Action Podcast, ASCO President Dr. Monica Bertagnolli joined ASCO CEO Dr. Clifford Hudis to discuss the disparities facing patients with cancer in rural areas. Dr. Bertagnolli touched on a number of ways to close the rural cancer care gap, from supporting the existing rural oncology workforce, to improving care delivery in rural areas, and increasing access to clinical trials and research. “We’re completely in the dark without research,” says Dr. Bertagnolli. It’s “the only way to understand what patients really need.”
Positive findings from fully enrolled cohorts in non-small cell lung cancer and metastatic breast cancer from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR™) Study will be presented in poster sessions at the 2019 ASCO Annual Meeting. In addition, the study is being expanded to include patients with active brain metastases and three new drug therapies. Learn more.
ASCO and Friends of Cancer Research (Friends) have commended the U.S. Food and Drug Administration (FDA) on four recently released draft guidance documents related to expanding clinical trial eligibility in a joint letter to Acting Commissioner Ned Sharpless, MD. Read more.
Early registration is now open for the ASCO Research Community Forum (RCF) 2019 Annual Meeting. The ASCO RCF Annual Meeting brings together physician investigators and research staff from across the country for two days of learning and collaboration. The meeting offers colleagues from a variety of types of research programs a unique platform to collaborate and develop solutions to common challenges with conducting oncology clinical trials.
Three completed cohorts reporting findings in non-small cell lung cancer, breast, and metastatic colorectal cancer from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR™) Study were presented in poster sessions during AACR Annual Meeting 2019. In addition, all seven participating pharmaceutical companies renewed their commitment to provide study drugs at no cost. Learn more.
ASCO is kicking off its advocacy campaign in support of increased funding for federal cancer research. The launch of this year’s advocacy effort comes as Congress is beginning its work to craft Fiscal Year (FY) 2020 appropriations bills. As part of the campaign, ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH) – a $2.5 billion increase from FY 2019 – and $6.5 billion to the National Cancer Institute (NCI).
Taking place September 22-23, 2019 at ASCO Headquarters in the Washington, DC metro area, this meeting is a unique opportunity for physician investigators and research staff from all types of oncology research programs to network and collaborate, share best practices, and develop solutions to common challenges with conducting oncology clinical trials. Registration will open May 1. Visit the RCF website to learn more, and to access other helpful resources and tools for research programs.
The Workshop on Development of Tissue-Agnostic, Biomarker-Based Indications, cohosted by ASCO, FDA, and Friends of Cancer Research, is now open for registration. The April 26 full-day event aims to bring together members of various sectors to identify clinical trial designs and strategies that can accelerate drug development based on biomarkers that are agnostic to tumor types. Learn more and register.